Literature DB >> 18579437

Characterization of naturally occurring parainfluenza virus type 2 (hPIV-2) variants.

O Terrier1, G Cartet, O Ferraris, F Morfin, D Thouvenot, S S Hong, B Lina.   

Abstract

BACKGROUND: Human parainfluenza viruses (hPIV) are respiratory pathogens responsible for upper and lower respiratory tract infections. In most labs, the clinical diagnosis of hPIV is routinely done using techniques based on the detection of viral antigens such as immunofluorescence assay or/and viral isolation. STUDY
DESIGN: Five hPIV-2 isolated from respiratory samples exhibited unusual phenotypic and antigenic characteristics. These isolates showed important syncytial cytopathic effect and failed to react with one specific monoclonal antibody. These variant strains were subsequently compared with hPIV-2 prototype strain by cellular and molecular techniques.
RESULTS: Both variant and prototype strains showed similar growth kinetics. Observation of plaque formation and syncytia assay indicated a more important fusogenic activity for the variant strains. Sequencing of fusion (F) and hemagglutinin-neuraminidase (HN) genes showed differences between the "atypical" hPIV-2 isolates and the Greer hPIV-2 prototype strain. These differences were analyzed with molecular modelling and structure prediction soft wares. A potential new glycosylation site in HN, in addition to minor changes observed in the predicted structure for the variant strains could explain their antigenic variation. Genetic changes in the fusion peptide and the cleavage site of F could also explain the difference observed in the fusion activity.
CONCLUSIONS: Continuous global viral surveillance is essential to monitor antigenic changes that may occur in nature particularly with regards to the implementation of diagnostic assays. The differences observed in F and HN between the prototype strain and clinical hPIV-2 variants could also provide new data for the analysis of Paramyxovirus fusion mechanisms and their pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579437     DOI: 10.1016/j.jcv.2008.05.007

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  Cytopathogenesis of Sendai virus in well-differentiated primary pediatric bronchial epithelial cells.

Authors:  Rémi Villenave; Olivier Touzelet; Surendran Thavagnanam; Severine Sarlang; Jeremy Parker; Grzegorz Skibinski; Liam G Heaney; James P McKaigue; Peter V Coyle; Michael D Shields; Ultan F Power
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

2.  Structures of the prefusion form of measles virus fusion protein in complex with inhibitors.

Authors:  Takao Hashiguchi; Yoshinari Fukuda; Rei Matsuoka; Daisuke Kuroda; Marie Kubota; Yuta Shirogane; Shumpei Watanabe; Kouhei Tsumoto; Daisuke Kohda; Richard Karl Plemper; Yusuke Yanagi
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-20       Impact factor: 11.205

3.  Characterization of a key residue for hyperfusogenic phenotype in human parainfluenza virus type 2 (hPIV-2) fusion glycoprotein.

Authors:  Jean-Christophe Le Bayon; Olivier Terrier; Gaëlle Cartet; Bruno Lina; Manuel Rosa-Calatrava
Journal:  Virus Genes       Date:  2013-06-08       Impact factor: 2.332

Review 4.  The challenges in developing effective canine infectious respiratory disease vaccines.

Authors:  Judy A Mitchell; Joe Brownlie
Journal:  J Pharm Pharmacol       Date:  2015-03-03       Impact factor: 3.765

5.  Human parainfluenza virus type 2 hemagglutinin-neuramindase gene: sequence and phylogenetic analysis of the Saudi strain Riyadh 105/2009.

Authors:  Fahad N Almajhdi; Mohamed S Alshaman; Haitham M Amer
Journal:  Virol J       Date:  2012-12-22       Impact factor: 4.099

6.  Genotype replacement of the human parainfluenza virus type 2 in Croatia between 2011 and 2017 - the role of neutralising antibodies.

Authors:  M Šantak; M Lang Balija; G Mlinarić Galinović; S Ljubin Sternak; T Vilibić-Čavlek; I Tabain
Journal:  Epidemiol Infect       Date:  2018-06-18       Impact factor: 4.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.